Pathogenic bacteria as vaccine vectors: Teaching old bugs new Tricks

Yale Journal of Biology and Medicine

Volumn 83, Issue 4, 2010, Pages 217-222

  Carleton, Heather A ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antigen expression; Attenuated bacteria; Bacterial vaccine vectors; Orally administered vaccines; Salmonella vaccines; Type III secretion system vaccines; Vaccine vectors; Vaccines adaptive immunity; Vaccines innate immunity

Indexed keywords

BACTERIAL VECTOR; LIVE ATTENUATED BACTERIAL VECTOR; UNCLASSIFIED DRUG; VACCINE; VIRULENCE ATTENUATED BACTERIAL VECTOR;

ANTIGEN EXPRESSION; AUXOTROPHIC MUTANT; BACTERIAL CELL; BACTERIAL STRAIN; CELL SURFACE; CELLULAR DISTRIBUTION; DRUG DELIVERY SYSTEM; DRUG POTENCY; HUMAN; IMMUNOGENICITY; IMMUNOSTIMULATION; INNATE IMMUNITY; NONHUMAN; REVIEW;

ADAPTIVE IMMUNITY; ANIMALS; BACTERIA; HUMANS; IMMUNITY, INNATE; VACCINES;

BACTERIA (MICROORGANISMS); MAMMALIA; SALMONELLA;

EID: 79953148544     PISSN: 00440086     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Kaech S, Ahmed R. Memory CD8+ T cell differentiation: initial antigen encounter triggers a developmental program in naive cells. Nat Immunol. 2001;2(5):415-22.
2. Wang S, Li Y, Shi H, Scarpellini G, Torres-Escobar A, Roland K, et al. Immune responses to recombinant pneumococcal PsaA antigen delivered by a live attenuated Salmonella vaccine. Infect. 2010;78(7):3258-71.
3. Russmann H, Shams H, Poblete F, Fu Y, Galan JE, Donis RO. Delivery of epitopes by the Salmonella type III secretion system for vaccine development. Science. 1998;281(5376):565- 8.
4. Evans DT, Chen L-M, Gillis J, Lin K-C, Harty B, Mazzara GP, et al. Mucosal priming of simian immunodeficiency virus-specific cytotoxic T-lymphocyte responses in rhesus macaques by the Salmonella type III secretion antigen delivery system. J Virol. 2003;77(4):2400-9.
5. Russmann H, Igwe E, Sauer J, Hardt W, Bubert A, Geginat G. Protection against murine listeriosis by oral vaccination with recombinant Salmonella expressing hybrid Yersinia type III proteins. J Immunol. 2001;167(1):357- 65.
6. Nishikawa H, Sato E, Briones G, Chen L-M, Matsuo M, Nagata Y, et al. In vivo antigen delivery by a Salmonella typhimurium type III secretion system for therapeutic cancer vaccines. J Clin Invest. 2006;116(7):1946-54.
7. Shams H, Poblete F, Russmann H, Galan JE, Donis RO. Induction of specific CD8+ memory T cells and long lasting protection following immunization with Salmonella typhimurium expressing a lymphocytic choriomeningitis MHC class I-restricted epitope. Vaccine. 2001;20(3-4):577-85.
8. Chinchilla M, Pasetti M, Medina-Moreno S, Wang J, Gomez-Duarte O, Stout R, et al. Enhanced immunity to Plasmodium falciparum circumsporozoite protein (PfCSP) by using Salmonella enterica serovar Typhi expressing PfCSP and a PfCSP-encoding DNA vaccine in a heterologous prime-boost strategy. Infect Immun. 2007;75(8):3769-79.
9. Germanier R, Fuer E. Isolation and characterization of Gal E mutant Ty 21a of Salmonella typhi: a candidate strain for a live, oral typhoid vaccine. J Infect Dis. 1975;131(5):553-8.
10. Calmette A. La Vaccination Preventive contre la Tuberculose par le BCG. Paris: Masson et Cie; 1927.
11. Medina E, Guzman CA. Use of live bacterial vaccine vectors for antigen delivery: potential and limitations. Vaccine. 2001;19(13-14):1573-80.
12. Garmory H, Leary S, Griffin K, Williamson E, Brown K, Titball R. The use of live attenuated bacteria as a delivery system for heterologous antigens. J Drug Target. 2003;11(8-10):471-9.
13. Galan JE, Curtiss R, 3rd. Virulence and vaccine potential of phoP mutants of Salmonella typhimurium. Microb Pathog. 1989;6(6):433- 43.
14. Hohmann E, Oletta C, Killeen K, Miller S. phoP/phoQ-deleted Salmonella typhi (Ty800) is a safe and immunogenic singledose typhoid fever vaccine in volunteers. J Infect Dis. 1996;173(6):1408-14.
15. Hoiseth SK, Stocker BA. Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines. Nature. 1981;291(5812):238-9.
16. Cersini A, Salvia AM, Bernardini ML. Intracellular multiplication and virulence of Shigella flexneri auxotrophic mutants. Infect Immun. 1998;66(2):549-57.
17. Bowe F, O'Gaora P, Maskell D, Cafferkey M, Dougan G. Virulence, persistence, and immunogenicity of Yersinia enterocolitica O:8 aroA mutants. Infect Immun. 1989;57(10):3234- 6.
18. Alexander JE, Andrew PW, Jones D, Roberts IS. Characterization of an aromatic amino acid-dependent Listeria monocytogenes mutant: attenuation, persistence, and ability to induce protective immunity in mice. Infect Immun. 1993;61(5):2245-8.
19. Roberts M, Maskell D, Novotny P, Dougan G. Construction and characterization in vivo of Bordetella pertussis aroA mutants. Infect Immun. 1990;58(3):732-9.
20. Attridge SR, Davies R, LaBrooy JT. Oral delivery of foreign antigens by attenuated Salmonella: consequences of prior exposure to the vector strain. Vaccine. 1997;15(2):155- 62.
21. Molina NC, Parker CD. Murine antibody response to oral infection with live aroA recombinant Salmonella dublin vaccine strains expressing filamentous hemagglutinin antigen from Bordetella pertussis. Infect Immun. 1990;58(8):2523-8.
22. Loessner H, Endmann A, Leschner S, Westphal K, Rohde M, Miloud T, et al. Remote control of tumour-targeted Salmonella enterica serovar Typhimurium by the use of L-arabinose as inducer of bacterial gene expression in vivo. Cell Microbiol. 2007;9(6):1529-37.
23. Bumann D. Regulated antigen expression in live recombinant Salmonella enterica serovar Typhimurium strongly affects colonization capabilities and specific CD4(+)-T-cell responses. Infect Immun. 2001;69(12):7493-500.
24. Orr N, Galen JE, Levine MM. Novel use of anaerobically induced promoter, dmsA, for controlled expression of fragment C of tetanus toxin in live attenuated Salmonella enterica serovar Typhi strain CVD 908-htrA. Vaccine. 2001;19(13-14):1694-700.
25. John M, Crean TI, Calderwood SB, Ryan ET. In vitro and in vivo analyses of constitutive and in vivo-induced promoters in attenuated vaccine and vector strains of Vibrio cholerae. Infect Immun. 2000;68(3):1171-5.
26. Frey J. Biological safety concepts of genetically modified live bacterial vaccines. Vaccine. 2007;25(30):5598-605.
27. Galan JE, Nakayama K, Curtiss R, 3rd. Cloning and characterization of the asd gene of Salmonella typhimurium: use in stable maintenance of recombinant plasmids in Salmonella vaccine strains. Gene. 1990;94(1):29-35.
28. Husband AJ. Novel vaccination strategies for the control of mucosal infection. Vaccine. 1993;11(2):107-12.
29. Kotton CN, Hohmann EL. Enteric pathogens as vaccine vectors for foreign antigen delivery. Infect Immun. 2004;72(10):5535-47.
30. Levine MM, Tacket CO, Sztein MB. Host- Salmonella interaction: human trials. Microbes Infect. 2001;3(14-15):1271-9.
31. Patel JC, Galan JE. Manipulation of the host actin cytoskeleton by Salmonella-all in the name of entry. Curr Opin Microbiol. 2005;8(1):10-15.
32. Pulendran B, Ahmed R. Translating innate immunity into immunological memory: implications for vaccine development. Cell. 2006;124(4):849-63.
33. Klebanoff CA, Gattinoni L, Restifo NP. CD8+ T-cell memory in tumor immunology and immunotherapy. Immunol Rev. 2006;211:214-24.
34. Yewdell JW, Haeryfar SM. Understanding presentation of viral antigens to CD8+ T cells in vivo: the key to rational vaccine design. Annu Rev Immunol. 2005;23:651-82.
35. Schaible UE, Collins HL, Kaufmann SH. Confrontation between intracellular bacteria and the immune system. Adv Immunol. 1999;71:267-377.
36. Mollenkopf H, Dietrich G, Kaufmann SH. Intracellular bacteria as targets and carriers for vaccination. Biol Chem. 2001;382(4):521-32.
37. Chen L-M, Briones G, Donis RO, Galan JE. Optimization of the delivery of heterologous proteins by the Salmonella enterica serovar Typhimurium type III secretion system for vaccine development. Infect Immun. 2006;74(10):5826-33.
38. Panthel K, Meinel KM, Sevil Domenech VE, Trulzsch K, Russmann H. Salmonella type III-mediated heterologous antigen delivery: a versatile oral vaccination strategy to induce cellular immunity against infectious agents and tumors. Int J Med Microbiol. 2008;298(1-2):99-103.
39. Galán JE. The Salmonella typhimurium type III protecin secretion system: an effective antigen delivery platform for cancer therapeutics. Drugs of the Future. 2007;32(11):1-6.
40. Galen JE, Pasetti MF, Tennant S, Ruiz-Olvera P, Sztein MB, Levine MM. Salmonella enterica serovar Typhi live vector vaccines finally come of age. Immunol Cell Biol. 2009;87(5):400-12.
41. Bueno SM, Gonzalez PA, Kalergis AM. Use of genetically modified bacteria to modulate adaptive immunity. Curr Gene Ther. 2009;9(3):171-84.